| CYP4F2基因多态性与华法林维持剂量关系的研究进展 |
| |
| 引用本文： | 谢爽,李一石.CYP4F2基因多态性与华法林维持剂量关系的研究进展[J].中国新药杂志,2011(13). |
| |
| 作者姓名： | 谢爽 李一石 |
| |
| 作者单位： | 中国医学科学院北京协和医学院阜外心血管病医院卫生部心血管药物临床研究重点实验室; |
| |
| 摘 要： | 华法林是目前临床上应用最广泛的口服抗凝药,其治疗安全范围窄,剂量个体差异大,临床应用中容易出现抗凝不当所致的并发症。近3年来,随着药物基因组学的快速发展,发现细胞色素P450酶4F2(CYP4F2)基因多态性(rs2108622)与华法林个体剂量差异相关。本文综述了近3年来在不同人种中进行的有关CYP4F2*3(rs2108622)与华法林的维持剂量关系的研究。大多数研究发现CYP4F2基因多态性与华法林维持剂量存在相关性,其中突变的T等位基因与华法林高剂量相关;CYP4F2*3可以解释1%～10%华法林剂量个体差异。
|
| 关 键 词： | 华法林 药物基因组学 CYP4F2 |
Research progress in association between CYP4F2 gene polymorphism and warfarin maintenance dose |
| |
| XIE Shuang,LI Yi-shi.Research progress in association between CYP4F2 gene polymorphism and warfarin maintenance dose[J].Chinese Journal of New Drugs,2011(13). |
| |
| Authors: | XIE Shuang LI Yi-shi |
| |
| Institution: | XIE Shuang,LI Yi-shi(Key Laboratory of Clinical Trial Research in Cardiovascular Drugs Ministry of Health,Cardiovascular Institute and Fuwai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China) |
| |
| Abstract: | Currently,warfarin is the most widely used oral anticoagulant in clinic.Since warfarin has narrow therapeutic window and significant individual differences in dose,it easily leads to complications due to improper anticoagulate therapy.In recent 3 years,as the rapid development of pharmacogenomics,it has been found that CYP4F2(cytochrome P450,family 4,subfamily F,polypeptide 2) gene polymorphism(rs2108622) relates to warfarin individual dosage requirement.We reviewed research progress in association between ... |
| |
| Keywords: | warfarin pharmacogenomics CYP4F2 |
| 本文献已被 CNKI 等数据库收录！ |
|
